Clinical trial · Observational
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance:A Multicenter Retrospective Study
NCT06202599CI-TRIAL-00073029completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of TKIs' resistance.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Sarcoma | Bone Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Refractory Tumor | Neoplasm | CURATED_BROADER | 0.78 |
| Soft Tissue Sarcoma | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fruquintinib | Drug | Fruquintinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Study group
- description
- Fruquintinib treatment group
- interventionNames
- Drug: Fruquintinib
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 4months
- description
- The time from the first administration of fruquintinib to the date of first documentation of disease progression or death, whichever occurred first.
Secondary outcomes (4)
- measure
- OS
- timeFrame
- 1year
- description
- OS was calculated from the use of fruquintinib until death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed bone or soft tissue sarcomas; 2. Progressed after several lines of therapy; 3. Previously treated with other TKIs before fruquintinib; 4. Received fruquintinib-based treatment; 5. Measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST) version1.1; 6. Eastern Cooperative Oncology Group (ECOG) performance status ≤3 Exclusion Criteria: 1. Failure to complete regular follow-up after administration. 2. Discontinued the fruquintinib-based treatment due to neither progression nor unacceptable toxicity.
References
Publications (0)
Data not yet available
No reference posted for this study.